Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1253-1264

  Valladares Ayerbes, Manuel ^a,b   Blanco, Moises ^b   Haz, Mar ^b   Medina, Vanessa ^b   Iglesias Diáz, Pilar ^b   Lorenzo Patiño, Maria J ^b   Reboredo, Margarita ^a   Santamarina, Isabel ^b   Figueroa, Angeĺica ^b   Antón Aparicio, Luis M ^a   Calvo, Lourdes ^a  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b University Hospital   (Spain)

Author keywords

Disseminated tumor cells; Gastrointestinal cancer; Micro RNA; Prognostic; Real time PCR

Indexed keywords

CYTOKERATIN ANTIBODY; MICRORNA;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DISSEMINATED CANCER; DISSEMINATED TUMOR CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION;

AGED; BONE MARROW; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KERATINS; MALE; MICRORNAS; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; PROGNOSIS; RNA STABILITY;

EID: 80053190218     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1112     Document Type: Article

References (51)

1. Malvezzi M, Arfé A, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2011. Ann Oncol. Advance Access published February 8, 2011. doi:10.1093/annonc/mdq774
2. Pantel K, Alix-Panabières C and Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 6: 339-351, 2009.
3. Schlimok G, Funke I, Bock B, Schweiberer B, Witte J and Riethmüller G: Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 8: 831-837, 1990. (Pubitemid 20148275)
4. Lindemann F, Schlimok G, Dirschedl P, Witte J and Riethmüller G: Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685-689, 1992.
5. Heiss MM, Allgayer H, Gruetzner KU, et al: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1: 1035-1039, 1995.
6. Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T and Ohno S: Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 73: 83-87, 1996. (Pubitemid 26026265)
7. Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner HJ, Riethmueller G and Schildberg FW: Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14: 1810-1817, 1996. (Pubitemid 26185456)
8. Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B and Juhl H: Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 227: 372-379, 1998. (Pubitemid 28131018)
9. Roder JD, Thorban S, Pantel K and Siewert JR: Micrometastases in bone marrow: prognostic indicators for pancreatic cancer. World J Surg 23: 888-891, 1999. (Pubitemid 29398468)
10. Leinung S, Würl P, Schönfelder A, Weiss CL, Röder I and Schönfelder M: Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res 9: 905-911, 2000. (Pubitemid 32110291)
11. Z'graggen K, Centeno BA, Fernandez-del Castillo F, Jimenez RE, Werner J and Warshaw AL: Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery 129: 537-546, 2001.
12. Gretschel S, Schick C, Schneider U, Estevez-Schwarz L, Bembenek A and Schlag PM: Prognostic value of cytokeratinpositive bone marrow cells of gastric cancer patients. Ann Surg Oncol 14: 373-380, 2007. (Pubitemid 46175278)
13. Funke I and Schraut W: Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 16: 557-566, 1998. (Pubitemid 28135599)
14. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M and Weitz J: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138: 1714-1726, 2010.
15. Steinert R, Hantschick M, Vieth M, Gastinger I, Kühnel F, Lippert H and Reymond MA: Influence of subclinical tumor spreading on survival after curative surgery for colorectal cancer. Arch Surg 143: 122-128, 2008. (Pubitemid 351281615)
16. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW, Kollermann J, Speicher MR and Pantel K: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 99: 2246-2251, 2002. (Pubitemid 34169046)
17. Croce CM: Oncogenes and cancer. N Engl J Med 358: 502-511, 2008.
18. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
19. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008. (Pubitemid 351185951)
20. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinico-pathologic features of colorectal cancer. Oncology 72: 397-402, 2007. (Pubitemid 351238155)
21. Li X, Zhang Y, Zhang Y, Ding J, Wu K and Fan D: Survival prediction of gastric cancer by a seven-microRNA signature. Gut 59: 579-585, 2010.
22. Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12: 2171-2176, 2008.
23. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, et al: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5: e10630, 2010.
24. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ and Hammond SM: A microRNA polycistron as a potential human oncogene. Nature 435: 828-833, 2005. (Pubitemid 40839734)
25. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
26. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M and Sobin LH: TNM Átlas. 5th edition. Springer-Verlag, Berlin, Heidelberg, 2005.
27. Valladares-Ayerbes M, Iglesias-Díaz P, Díaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolín S, Calvo L and Antón-Aparicio L: Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol 135: 1185-1195, 2009.
28. Borgen E, Naume B, Nesland, et al: Standardization of the immunocytochemical detection of cancer cells in bone marrow and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1: 377-388, 1999.
29. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J and Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
30. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
31. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802, 2005. (Pubitemid 41215488)
32. Hosch SB, Steffani KD, Scheunemann P and Izbicki JP: Micrometastases from HBP malignancies and metastatic cancer. Hepatob Pancreat Surg 9: 583-591, 2002. (Pubitemid 36305104)
33. Offner S, Schmaus W, Witter K, Baretton GB, Schlimok G, Passlick B, Riethmüller and Pantel K: p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci USA 96: 6942-6946, 1999. (Pubitemid 29274989)
34. Kakeji Y, Maehara Y, Shibahara K, Hasuda S, Tokunaga E, Oki E and Sugimachi K: Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. Gastric Cancer 2: 46-51, 1999.
35. Gretschel S, Astrosini Ch, Vieth M, Jöns Th, Tomov T, Höcker M, Schlag PM and Kemmner W: Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients. Eur J Surg Oncol 34: 642-647, 2008. (Pubitemid 351681937)
36. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K and Izbicki JR: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97: 1840-1847, 2005. (Pubitemid 43033904)
37. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G and Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Modern Pathol 20: 1183-1190, 2007. (Pubitemid 47609067)
38. Benes V and Castoldi M: Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50: 244-249, 2010.
39. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A and Yakhini Z: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4: e8003, 2009.
40. Haaften G and Agami R: Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 24: 1-4, 2010.
41. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H and Takahashi T: Identification of hypoxia-inducible factor-1A as a novel target for miR-17-92 microRNA cluster. Cancer Res 68: 5540-5545, 2008.
42. Yan H, Xue G, Mei Q, Wang Y, Ding F, Liu M, Lu M, Tang Y, Yu H and Sun S: Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 28: 2719-2732, 2009.
43. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA and Thomas-Tikhonenko A: The myc-miR-17-92 axis blunts TGF beta signaling and production of multiple TGF beta-dependent antiangiogenic factors. Cancer Res 70: 8233-8246, 2010.
44. Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F and Dominguez G: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47: 794-802, 2008.
45. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S et al: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11: 136-146, 2010.
46. Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K and Mori M: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 36: 1089-1095, 2010.
47. Lagerstedt KK, Kristiansson E, Lönnroth C, Andersson M, Iresjö BM, Gustafsson A, Hansson E, Kressner U, Nordgren S, Enlund F and Lundholm K: Genes with relevance for early to late progression of colon carcinoma based on combined genomic and transcriptomic information from the same patients. Cancer Informatics 9: 79-91, 2010.
48. Nicole MA, White NMA, Fatoohi E, Metias M, Jung K, Stephan C and Yousef GM: Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 8: 75-84, 2011.
49. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ, Lazo JS, Wang Z, Zhang L and Yu J: MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69: 8157-8165, 2009.
50. Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, Brünner N, Baker A, Møller S and Nielsen HJ: High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28: 27-38, 2011.
51. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Ørntoft TF and Andersen CL: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424, 2008.